Viewing Study NCT02879318

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:54 AM
Ignite Modification Date: 2026-02-21 @ 10:09 PM
Study NCT ID: NCT02879318
Status: COMPLETED
Last Update Posted: 2025-03-24
First Post: 2016-08-22
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
Sponsor: Canadian Cancer Trials Group
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Pancreatic Adenocarcinoma View
Keywords: